The specialist cancer drug discovery and development business has today announced a deal which is set to crystallise value and near term cash generation from what was viewed by many to be a non-core asset for Sareum. Sareum has entered into an agreement with a Shanghai main market-listed Chinese specialty pharmaceutical company; the Licensee will make an initial upfront payment of £50,000 to Sareum, with a further Development Payment of c. £0.9m due on the earlier of achieving cer
26 Mar 2020
Global Licensing Deal for FLT3+Aurora Programme
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Global Licensing Deal for FLT3+Aurora Programme
Sareum Holdings plc (SAR:LON) | 26.8 1.7 30.5% | Mkt Cap: 26.4m
- Published:
26 Mar 2020 -
Author:
Derren Nathan -
Pages:
9
The specialist cancer drug discovery and development business has today announced a deal which is set to crystallise value and near term cash generation from what was viewed by many to be a non-core asset for Sareum. Sareum has entered into an agreement with a Shanghai main market-listed Chinese specialty pharmaceutical company; the Licensee will make an initial upfront payment of £50,000 to Sareum, with a further Development Payment of c. £0.9m due on the earlier of achieving cer